X

Trial Profile

A Phase 2B, Randomized, Double Blind, Active Comparator, Multicenter, Safety, and Efficacy Trial of ATX-101 in Subjects Undergoing Total Knee Arthroplasty

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bupivacaine (Primary) ; Bupivacaine
Indications Postoperative pain
Focus Pharmacokinetics
Acronyms SPARK
Sponsors Allay Therapeutics

Most Recent Events

26 Jun 2024 Status changed from active, no longer recruiting to discontinued.
11 Apr 2024 According to an Allay Therapeutics media release, Prof. Hemant Pandit is leading investigator in this trial.
11 Apr 2024 Primary endpoint has been met. (Area under the curve (AUC) for the Numeric Rating Scale at Rest (NRS-R) of pain intensity.), according to an Allay Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com